The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...

A new survey from SiriusXM Media details the issues that many people have with the current state of TV drug ads—and ...

While argenx has been able to demonstrate the merit of its FcRn drug Vyvgart in multiple autoimmune indications, not every ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

After a three-decade drought of new antibiotics to treat gonorrhea, the FDA has signed off on two first-in-class oral ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...